Atlas Trials

Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations

Clinical trial NCT05507606 · UNKNOWN

Trial details

NCT number
NCT05507606
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Non Small Cell Lung Cancer
Start date
2021-08-01
Primary completion
2023-08-01
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.